Athera Biotechnologies has completed a 57 million SEK financing from current major owners, The Foundation for Baltic and East European Studies (Östersjöstiftelsen), Industrifonden and Linc AB, together with new investor
The latest biotech news
BioInvent International and ThromboGenics NV announce that they have agreed to amend their long-standing agreement, which covers the co-development of the novel anti-PlGF monoclonal antibody products TB-403 and THR-317. The
The financing was led by a group of private investors in Norway and the company will use these funds to advance lead product CyPep-1 into a Phase I clinical trial.
BerGenBio announces the award of a NOK 24 million (USD 2.85m) grant from Innovasjon Norge to support the clinical development of BGB324 in combination with Merck & Co.’s KEYTRUDA (pembrolizumab)
Athera Biotechnologies announces that the the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to the fully human antibody PC-mAb, for the treatment of patients with end
LEO Pharma announces an investment in the biotechnology company Novopyxis to support the development of an early-stage drug delivery device designed to increase the penetration of topical treatments in the
Swedish Cantargia and Panorama Research Inc, a California based specialist antibody developer, have entered into a collaboration agreement to jointly accelerate Cantargia’s second program directed towards autoimmune and inflammatory diseases.
What can researchers, investors, and funding agencies do to unlock biotech’s potential? The European life science industry has great potential to improve patient care, solve public health challenges, and drive
Oslo Cancer Cluster (OCC) is currently involved in a big European collaboration through the cluster-to-cluster project PERMIDES. The project aims to utilize novel IT-solutions to accelerate drug development in biotech companies.
BerGenBio announces that the first patients have been dosed and continue on therapy in a Phase I/II randomised trial evaluating the addition of BerGenBio’s selective, potent and orally bio-available AXL
Cantargia announces that the company has received an Intention to Grant notice from the European Patent Office for its patent application for the CAN04 product candidate. The patent application, with
Idogen announces that the European Patent Office will formally grant a patent application, covering the company’s tolerogenic vaccine technology. The EPO approval strengthens the company’s patent portfolio for the vaccine
Pelago Bioscience and Chemical Biology Consortium Sweden (CBCS), the chemical biology facility at Karolinska Institutet and SciLifeLab (Science for Life Laboratory) will collaborate to develop high throughput automated CETSA-based Target
UK’s Sygnature Discovery will collaborate with Swedish biotech company Pelago Bioscience to provide target engagement assays with Pelago’s patented Cellular Thermal Shift Assay (CETSA) method. Pelago’s CETSA method enables measurements
The Umeå based company Betagenon receives €1,8 million, from EU’s sought after Horizon 2020 program, to close the gap to the market for their drug against obesity induced diabetes and
AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has accepted the first Biologics License Application (BLA) for durvalumab, a
Earlier today, SwedenBIO presented its annual report on the Swedish drug discovery and development pipeline, showing for example that the number of clinical stage drug development projects has increased from
PCI Biotech has initiated a process with the objective to carry out a share issue in the range of NOK 40-50 million by the end of November 2016. Two of
Symcel has partnered with TiKa Diagnostics and St. George’s University of London, for the use of its microcalorimetry technology in testing mycobacteria and for antimicrobial peptide (AMP) studies. The project
For the second year running, Denmark’s biotech sector is awarded a global top three ranking by Scientific American Worldview and is praised for its generous public sector investment and speedy
Takara Bio Europe AB, which specializes in human induced pluripotent stem cell (hiPSC)-derived cells and medias for scale-up and differentiation, has expanded its offering of tools for drug discovery and
Albumedix and Hebei Changshan Biochem Pharma announced before the summer that they have entered into a supply agreement for the development of a novel type II diabetes treatment that enables